N/A N=60 Hyperglycemia in Renal Transplantation
Diabetes · End Stage Renal Disease
Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=543 Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Renal Transplantation
Primary: Percentage of Participants Who Survived With a Graft at 12 Months Post-Transplant — 85.9; 88.0; 84.8 percentage of participants
N/A N=120 Effect of Remote Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation
Kidney Diseases · Kidney Failure, Chronic · Kidney Failure
Primary: Plasma Creatine Concentration of the Recipients — 849.5; 878.5; 771.0; 776.5 μmol/l
N/A N=2 Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
Multiple Myeloma · Amyloidosis
Primary: Number of Participants Without Renal Allograft Rejection at 6 Months Post-transplant — 1 Participants
Phase 4 N=11 Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients
Renal Transplant Rejection · Transplants and Implants
Primary: Composite End Point of Acute Rejection, Graft Loss or Patient Death — 1; 1; 0; 0 participants
Phase 4 N=26 Panel Reactive Antibody (PRA) Reduction in Sensitized Patients Awaiting Renal Transplantation
End Stage Renal Disease
Primary: The Percent of Sensitized Patients Treated With PRA Reduction Pharmacological Therapy, Including Cytogam, Who Become Cross-match Compatible With Potential Living Donor…
Phase 2 N=31 Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation
Kidney Transplantation
Primary: The Rate of Allograft Rejection — 0; 0 participants
N/A N=655 Aortoiliac Stenosis in Kidney Transplantation
Aorto-Iliac Arterial Stenosis · Peripheral Arterial Disease · Kidney Transplant Failure
Primary: Patient Survival — 322; 48; 6 Participants
N/A N=104 IV Insulin Protocol in Diabetes and Renal Transplantation
Kidney Transplantation · Diabetes · Hyperglycemia
Primary: Delayed Graft Function — 8; 12 participants
Phase 2 N=7 Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients
Diabetes Mellitus, Type I
Primary: Insulin Independence With Both an HbA1c ≤ 6.5% and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant or a Reduction in HbA1c of at Least 1 Point…
Phase 3 N=90 Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients
Osteoporosis · Chronic Kidney Disease
Primary: Percent Change in BMD at the Total Lumbar Spine From Baseline to Month 12 — 4.5; -0.3 percent change — p=<0.001
Phase 4 N=10 Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
End Stage Renal Disease · Hepatitis C
Primary: Viral Response at Week 12 — 10 Participants
Phase 2 N=5 Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
Kidney Transplantation · Kidney Failure, Chronic
Primary: Number of Participants Successfully Withdrawn Off of Immunosuppressant Medication for 104 Weeks — 3 participants
N/A N=88 HLA-Identical Sibling Renal Transplant Tolerance
Immunosuppression · Kidney Transplantation · Graft Rejection
Primary: The Ability to Withdraw Immunosuppression as Above 24 Months Post-transplant — 6 Participants
Phase 4 N=10 Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients
End-Stage Renal Disease · Hepatitis C
Primary: Number of Participants With Grade 3 or Higher Treatment-related Adverse Events as US Department of Health and Human Services Common Terminology of Adverse Events (CTCAE)…
Phase 4 N=2,037 Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)
End Stage Renal Disease (ESRD) · Chronic Kidney Disease (CKD) · Hemodialysis
Primary: Incidence of Failure on the Composite of Treated Biopsy-proven Acute Rejection (tBPAR) or Estimated Glomerular Filtration Rate (eGFR) < 50 mL/Min/1.73m2. — 489; 456…
N/A N=42 Improving Adherence in Nonadherent Kidney Transplant Patients
Medication Adherence · Kidney Transplantation
Primary: Change in Number of Patients Being Adherent/Non-aherent After the Intervention — 15; 30; 34; 35 Participants
N/A N=40 Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens
End Stage Renal Failure With Renal Transplant
Primary: Change in T Cell & B Cell Generation — 1.05; 0.93; 0.8; 1.12 Mean % of Treg cells in peripheral blood
Phase 2 N=12 Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection
Kidney Failure
Primary: Serum Creatinine Concentration — 112 umol/L
N/A N=167 Transplant Navigator Intervention to Overcome Barriers to Kidney Transplantation
End Stage Renal Disease
Primary: Number of Steps Completed in Transplant Process — 1.0; 2.8 steps per participant
Phase 2 N=13 A Dose Escalation Study in de Novo Renal Transplantation
Kidney Transplantation
Primary: Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0. — 2; 4; 7; 0 Participants
N/A N=44 Low Dose Thymoglobin in Renal Transplant Patients
Acute Renal Failure
Primary: Rates of Acute Cellular Rejection Between Study Group — 4; 2 Number of rejection — p=<0.05
Phase 4 N=180 Improved Induction and Maintenance Immunosuppression in Kidney Transplantation
End-stage Renal Disease
Primary: Chronic Allograft Nephropathy (Cumulative Calcineurin-inhibitor Nephrotoxicity/Transplant Nephropathy) Per Protocol Surveillance Kidney Biopsies (Banff Grading…
N/A N=105 Conventional Laparoscopic Versus Laparoendoscopic Single Site Donor Nephrectomy in Living Donor Kidney Transplantation
Living Donors · Nephrectomy · Kidney Transplantation
Primary: The Primary End Point of the Study Was the Mean/Median Number of Days Postsurgery Required for Each Group to Return to 100% Functioning Capacity. — 43; 45 days
Phase 3 N=78 REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy
Liver Transplantation
Primary: Renal Function Assessed by Estimated Glomerular Filtartion Rate (eGFR) — 85.50; 80.26 mL/min/1.73m^2 — p=0.3013
Phase 1 N=2 Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)
Kidney Failure, Chronic · Renal Insufficiency
Primary: Number of Participants With Successful Withdrawal of Immunosuppression — 2 Participants
Phase 2 N=26 Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant
Kidney Transplant
Primary: Number of Subjects With Antibody-Mediated Rejection (AMR) in the First 3 Months After Living Donor Kidney Transplantation — 2 Participants
Phase 2 N=2 Renal Allograft Tolerance Through Mixed Chimerism
End Stage Renal Disease
Primary: Successful Withdrawal of Immunosuppressive Therapy — 2 Participants
N/A N=416 Reducing Disparities in Living Donor Transplant Among African Americans
Kidney Transplant
Primary: Percent of Patients With at Least One Inquiry From a Potential Living Donor — 15.63; 15.63; 15.77; 15.87 percentage of participants
N/A N=135 Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients
Kidney Transplant
Primary: Employment Status — 21; 2 Participants